biol gicas < biologic < biological

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by biologic

Number of relevant bibliographic references: 315.
[20-40] [0 - 20][0 - 50][40-60]

Ident.	Authors (with country if any)	Title
000743 (2019)	Amruta Trivedi [Australie] ; Constance Katelaris [Australie]	The use of biologic agents in the management of uveitis.
000853 (2019)	Luca Quartuccio [Italie] ; Ivan Giovannini [Italie] ; Stefano Pizzolitto [Italie] ; Maurizio Scarpa [Italie] ; Salvatore De Vita [Italie]	Seronegative Arthritis and Whipple Disease: Risk of Misdiagnosis in the Era of Biologic Agents
000866 (2019)	Gulsen Ozen [États-Unis] ; Sofia Pedro [États-Unis] ; Rebecca Schumacher [États-Unis] ; Teresa A. Simon [États-Unis] ; Kaleb Michaud [États-Unis]	Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
000880 (2019)	Ajinkya Pawar [États-Unis] ; Rishi J. Desai [États-Unis] ; Daniel H. Solomon [États-Unis] ; Adrian J. Santiago Ortiz [États-Unis] ; Sara Gale [États-Unis] ; Min Bao [États-Unis] ; Khaled Sarsour [États-Unis] ; Sebastian Schneeweiss [États-Unis] ; Seoyoung C. Kim [États-Unis]	Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
000884 (2019)	Gulsen Ozen ; Sofia Pedro ; Bryant R. England ; Bella Mehta ; Frederick Wolfe ; Kaleb Michaud	Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease‐Modifying Antirheumatic Drugs
000894 (2019)	Emma L. Simpson [Royaume-Uni] ; Shijie Ren [Royaume-Uni] ; Emma S. Hock [Royaume-Uni] ; John W. Stevens [Royaume-Uni] ; Aymeric Binard [France] ; Yves-Marie Pers [France] ; Rachel Archer [Royaume-Uni] ; Suzy Paisley [Royaume-Uni] ; Matthew D. Stevenson [Royaume-Uni] ; Chloé Herpin [France] ; Salah Ghabri [France]	Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.
000914 (2019)	Takafumi Naito [Japon] ; Junya Ohshiro [Japon] ; Hikaru Sato [Japon] ; Eiji Torikai [Japon] ; Motohiro Suzuki [Japon] ; Noriyoshi Ogawa [Japon] ; Junichi Kawakami [Japon]	Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients.
000954 (2019)	Diederik De Cock [Belgique] ; Patrick Verschueren [Belgique]	Primus inter pares: the choice of biologic drugs in rheumatoid arthritis.
000987 (2019)	Denis Choquette [Canada] ; Louis Bessette [Canada] ; Evo Alemao [États-Unis] ; Boulos Haraoui [Canada] ; Roelien Postema [Royaume-Uni] ; Jean-Pierre Raynauld [Canada] ; Louis Coupal [Canada]	Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
000998 (2019)	Heather L. Gelhorn [États-Unis] ; Zaneta Balantac [États-Unis] ; Christopher S. Ambrose [États-Unis] ; Yen N. Chung [États-Unis] ; Brian Stone [États-Unis]	Patient and physician preferences for attributes of biologic medications for severe asthma
000A29 (2019)	G. Carlino [Italie] ; M. Fornaro ; L. Santo ; R. Bucci ; A. Semeraro ; L. Quarta ; F. D'Onofrio ; A. Marsico ; C. Zuccaro ; P C Falappone ; D. Mazzotta ; F P Cantatore ; M. Muratore ; F. Iannone	Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE).
000A50 (2019)	Manuel Camean-Castillo [Espagne] ; Vicente Gimeno-Ballester [Espagne] ; Esmeralda Rios-Sanchez [Espagne] ; Silvia Fenix-Caballero [Espagne] ; Miguel Vázquez-Real [Espagne] ; Emilio Alegre-Del Rey [Espagne]	Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients.
000B09 (2019)	Ariane Klein [Allemagne] ; Jens Klotsche [Allemagne] ; Boris Hügle [Allemagne] ; Kirsten Minden [Allemagne] ; Anton Hospach [Allemagne] ; Frank Weller-Heinemann [Allemagne] ; Tobias Schwarz [Allemagne] ; Frank Dressler [Allemagne] ; Ralf Trauzeddel [Allemagne] ; Markus Hufnagel [Allemagne] ; Ivan Foeldvari [Allemagne] ; Michael Borte [Allemagne] ; Jasmin Kuemmerle-Deschner [Allemagne] ; Jürgen Brunner [Autriche] ; Prasad Thomas Oommen [Allemagne] ; Dirk Föll [Allemagne] ; Klaus Tenbrock [Allemagne] ; Andreas Urban [Allemagne] ; Gerd Horneff [Allemagne]	Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
000B89 (2019)	Juan Shan [République populaire de Chine] ; Jiabi Zhang [République populaire de Chine]	Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis.
000C01 (2019)	Martijn J H. Doeleman ; Erik M. Van Maarseveen [Pays-Bas] ; Joost F. Swart	Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis.
000D65 (2019)	Nadira B. Mothojakan ; Janki Gore ; Muhammad K. Nisar	Does biologic survival depend on co-prescribed methotrexate dose in established rheumatoid arthritis? A real-world study
000D69 (2019)	Gabriella Giancane [Italie] ; Valentina Muratore [Italie] ; Valentina Marzetti [Italie] ; Neus Quilis [Italie] ; Belen Serrano Benavente [Italie] ; Francesca Bagnasco [Italie] ; Alessandra Alongi [Italie] ; Adele Civino [Italie] ; Lorenzo Quartulli [Italie] ; Alessandro Consolaro [Italie] ; Angelo Ravelli [Italie, Russie]	Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era
000D92 (2019)	Natalie Duong [États-Unis] ; Kevin Curley [États-Unis] ; Annie Brown [États-Unis] ; Alexander Campanelli [États-Unis] ; Mai Anh Do [États-Unis] ; Daniel Levy [États-Unis] ; Adarsh Tantry [États-Unis] ; Gerard Marriott [États-Unis] ; Biao Lu [États-Unis]	Decoy exosomes as a novel biologic reagent to antagonize inflammation
000E15 (2019)	Saara Huoponen [Finlande] ; Kalle J. Aaltonen [Finlande] ; Jaana Viikinkoski [Finlande] ; Jarno Rutanen [Finlande] ; Heikki Relas [Finlande] ; Kirsi Taimen [Finlande] ; Kari Puolakka [Finlande] ; Dan Nordström [Finlande] ; Marja Blom [Finlande]	Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
000E25 (2019)	Debendra Pattanaik ; Sandeep Gupta ; Syed Islam ; Kunal Singhal ; Syed Raza	Conversion of Tuberculosis Screening Tests During Biologic Therapy Among Veteran Patient Population With Rheumatic Disease
000E96 (2019)	Che-Mai Chang [Taïwan] ; Yu-Wen Hsu [Taïwan] ; Henry Sung-Ching Wong [Taïwan] ; James Cheng-Chung Wei [Taïwan] ; Xiao Liu [États-Unis] ; Hsien-Tzung Liao [Taïwan] ; Wei-Chiao Chang [Taïwan]	Characterization of T-Cell Receptor Repertoire in Patients with Rheumatoid Arthritis Receiving Biologic Therapies

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "biologic" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "biologic" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    biologic
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021